<DOC>
	<DOCNO>NCT00657852</DOCNO>
	<brief_summary>The aim study prospectively evaluate efficacy two intravenous infusion pamidronate 90 mg , associate calcium calcidiol , early post-transplant period , bone loss liver transplant recipient , asses safety treatment .</brief_summary>
	<brief_title>Efficacy Pamidronate Treatment Bone Loss Associated With Liver Transplant</brief_title>
	<detailed_description>Patients diagnose chronic advanced liver disease await orthotopic liver transplantation eligible take part study . Patients exclude study young 18 year , receive multiorgan transplant retransplant , patient previous allergy bisphosphonates . Previous treatment fluoride , estrogens , selective estrogen receptor modulators bisphosphonates another reason exclusion , well therapy glucocorticoid last 6 month transplantation . None patient previous history disorder , liver disease , know affect bone metabolism . Study Design Conduct The study 1-year prospective , randomize , double-blind , placebo-controlled trial conduct 10 center Spain . Immunosuppression All patient receive microemulsion cyclosporine A ( CsA ) primary immunosuppressive agent , combination glucocorticoid . Additionally , mycophenolate mofetil associate accord usual clinical practice center . In case , glucocorticoid progressively taper first year . Intervention Patients receive oral calcium ( 500 mg twice daily ) oral 25-hydroxy vitamin D ( 16000 UI every 15 day ) , inform consent study obtain exploratory screen do . Within day 7-12 engraftment , recruit transplanted patient ( randomize either experimental placebo group . Patients treatment group receive single dose 90 mg disodium pamidronate within day 7-12 3 month liver transplantation , dilute 500 ml 5 % glucose serum administer 4-hour continuous intravenous infusion . Patients placebo group receive 500 ml 5 % glucoside serum infusion . Treatment oral calcium vitamin D maintain 1 year transplantation . Study Endpoints The primary endpoint study change bone mineral density ( BMD ) , quantify dual energy X-ray absorptiometry ( DXA ) safety pamidronate record adverse event . Secondary endpoint include incidence skeletal fracture , assessment radiological vertebral fracture ( symptomatic asymptomatic ) , development nonvertebral fracture . Evaluation Five study visit schedule : transplantation , within day 7-12 liver transplantation 3 , 6 12 month liver transplantation .</detailed_description>
	<mesh_term>Bone Diseases</mesh_term>
	<mesh_term>Metabolic Diseases</mesh_term>
	<mesh_term>Bone Diseases , Metabolic</mesh_term>
	<mesh_term>Liver Extracts</mesh_term>
	<mesh_term>Pamidronate</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>diagnose chronic advance liver disease await orthotopic liver transplantation young 18 year receive multiorgan transplant retransplant previous allergy bisphosphonates Previous treatment fluoride , estrogens , selective estrogen receptor modulators bisphosphonates therapy glucocorticoid last 6 month transplantation previous history disorder , liver disease , know affect bone metabolism .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>pamidronate , bone loss , liver transplantation</keyword>
</DOC>